A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-22 and is reviewed periodically as new material appears.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
== Plasticity == Cell plasticity is the idea that cells can switch phenotypes in response to environmental cues. In the context of regeneration, this environmental cue is damage or injury to a limb. Cell plasticity is closely related to dedifferentiation, implying that a cell with ‘plasticity’ can dedifferentiate to change phenotypes. Cell plasticity suggests that cells can change phenotypes slightly; not fully de-differentiating, to serve a better function. A strong example of this is lens regeneration in the newt.
=== October === 1 October – A ban on single-use plastic cutlery, plates and polystyrene trays comes into force in England. 2 October – NHS doctors in England begin a 72-hour strike as their dispute over pay and conditions continues. Education Secretary Gillian Keegan announces plans to ban pupils from using mobile phones at schools, both in lessons and during breaktime. A gas tank explodes at the Severn Trent Green Power site in Cassington, Oxfordshire, after it is struck by lightning. A boy is taken to hospital in a critical condition along with a man in his 50s after both are hit by lightning during a football match at The Sele School in Hertford. 3 October – Appearing at Sheffield Crown Court, a 13-year-old boy admits causing the death of Marcia Grant, 60, by running her over with her own car in the Greenhill area of Sheffield in April 2023. Following a trial at Worcester Crown Court, food processing factory worker Garry Jones, who contaminated food destined for Nando's with plastic gloves, plastic bags and metal ring pulls is sentenced to three years in prison. 4 October – Sunak confirms plans to replace A Levels and T Levels in England with a new qualification called the Advanced British Standard. 5 October – Historic England says it has discovered damage to Hadrian's Wall next to the felled Sycamore Gap Tree. An inquest is opened and adjourned into the M53 motorway coach crash. 8 October – Part of the Grade II listed Old Courthouse in Cockermouth, Cumbria, collapses into the River Cocker.
=== Macrocyclic CSPs === An interesting way of achieving chiral distinction on a CSP is the use of selectors with chiral cavity. These chiral selectors are attached to the stationary phase support material. In this category, there are basically three types of cavity chiral selectors namely cyclodextrins, crown ethers and macrocyclic glycopeptide antibiotics. Among these cyclodextrin based CSP is popular. In this type of CSPs the enantioselective guest-host interaction governs the chiral distinction.
Sources: en.wikipedia.org
anorexia lethargy profuse watery to bloody diarrhea (bloody diarrhea is more common in dogs with parvovirus than cats) vomiting (most common in cats) Clinical laboratory findings include (but are not limited to):
Immunosuppressants Non-steroidal anti-inflammatory drugs (NSAIDs) and salicylates Inhibitors of thyrosine kinases Opiates Treatment for benign prostatic hyperplasia Hormonal treatments and antiadrenergic drugs Antibiotics, antifungals, antiparasites, antivirals, and antimalarials Antidepressants Anti-gastroesophageal reflux drugs Anti-epileptic drugs Antihypertensive drugs Certain medications in the following classes of drugs may affect male sexual libido or sexual function**:
=== Late onset form === The Late-onset (LOPD) form differs from the infantile-onset principally in the relative lack of cardiac involvement. The onset has a slower progression and can present at any decade of life. Cardiac involvement may occur but is milder than in the infantile form. Skeletal involvement is more prominent with a predilection for the lower limbs. Late-onset features include impaired cough, recurrent chest infections, hypotonia, progressive muscle weakness, delayed motor milestones, difficulty swallowing or chewing, and reduced vital capacity. Variability in the age of onset, severity, and symptoms, between those as genetically similar as identical twins, indicates that there may be epigenetic - or secondary factors - influencing disease presentation. Prognosis depends on the age of onset of symptoms with a better prognosis being associated with later onset disease.
Sources: en.wikipedia.org
Noradrenergic and serotonergic nuclei in the ARAS are involved in the regulation of the REM sleep cycle and function as "REM-off" cells, with amphetamine's effect on norepinephrine and serotonin contributing to the suppression of REM sleep and a possible reduction of cataplexy at high doses. The American Academy of Sleep Medicine (AASM) 2021 clinical practice guideline conditionally recommends dextroamphetamine for the treatment of both type 1 and type 2 narcolepsy. Treatment with pharmaceutical amphetamines is generally less preferred relative to other stimulants (e.g., modafinil) and is considered a third-line treatment option. Medical reviews indicate that amphetamine is safe and effective for the treatment of narcolepsy. Amphetamine appears to be most effective at improving symptoms associated with hypersomnolence, with three reviews finding clinically significant reductions in daytime sleepiness in patients with narcolepsy. Additionally, these reviews suggest that amphetamine may dose-dependently improve cataplexy symptoms. However, the quality of evidence for these findings is low and is consequently reflected in the AASM's conditional recommendation for dextroamphetamine as a treatment option for narcolepsy.
=== Small proteins === Small proteins typically have a tertiary structure that is maintained by disulphide bridges (cysteine-rich proteins), metal ligands (metal-binding proteins), and or cofactors such as heme.
=== Severe intoxication === As of 2007 there is no known antidote or reversal agent for caffeine intoxication. Treatment of mild caffeine intoxication is directed toward symptom relief; severe intoxication may require peritoneal dialysis, hemodialysis, or hemofiltration. Intralipid infusion therapy is indicated in cases of imminent risk of cardiac arrest in order to scavenge the free serum caffeine.
The dentinal tubules contain the cytoplasmic extensions of odontoblasts that once formed the dentin and maintain it. The cell bodies of the odontoblasts are aligned along the inner aspect of dentin against a layer of predentin where they also form the peripheral boundary of the dental pulp Because of dentinal tubules, dentin has a degree of permeability, which can increase the sensation of pain and the rate of tooth decay. The strongest held theory of dentinal hypersensitivity suggests that it is due to changes in the dentinal fluid associated with the processes, possibly a type of hydrodynamic mechanism. Dentin is a bone-like matrix that is porous and yellow-hued material. It is made up, by weight, of 70–72% inorganic materials (mainly hydroxylapatite and some non-crystalline amorphous calcium phosphate), 20% organic materials (90% of which is collagen type 1 and the remaining 10% ground substance, which includes dentin-specific proteins), and 8–10% water (which is adsorbed on the surface of the minerals or between the crystals). Because it is less mineralized than enamel, it decays more rapidly and is subject to severe cavities if not properly treated, but due to its elastic properties, it is good support for enamel. Its flexibility prevents the brittle enamel fracturing during tooth preparation. In areas where both primary and secondary mineralization have occurred with complete crystalline fusion, these appear as lighter rounded areas on a stained section of dentin and are considered globular dentin.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.